The principal technique of hormonal methods of contraception, based on original studies by Pincus et al. (1958) , has relied on the joint action of an oestrogen (mestranol) and a progestogen (norethynodrel) given cyclically for 20 days monthly. Combinations of other progestogens with either mestranol or ethinyloestradiol have also been studied. The biological and clinical basis of the antifertility effects of these agents were reviewed by Diczfalusy (1965) and by Rudel and Kincl (1966) . The contraceptive mechanisms were described as (1) inhibition of ovulation, by both the oestrogen and the progestogen; and, fTom the anti-oestrogenic action of the progestogen, (2) a suppressed endometrium unfavourable to nidation, with (3) a cervical mucus hostile to spermatozoal motility. Definitive data on human tubal physiology relating to these agents have not been reported. Mestranol or ethinyloestradiol, given early and with regularity before ovulation, consistently inhibits its occurrence (Rudel and Martinez-Manautou, 1964; MartinezManautou and Rudel, 1966). Similar observations were made for ethinyloestradiol by Greenblatt et al. (1954). Thus, with the anti-ovulatory role of oestrogen and the anti-oestrogenic effects of progestogen defined, the concept of sequential therapy evolved-that is, early oestrogen for inhibition of ovulation, and later oestrogen plus progestogen to promote maturation of the endometrium with regular withdrawal bleeding. Oestrogen and progestogen, used concomitantly or sequentially, suppress the hypothalamic-pituitary-gonadal cycle, thus preventing ovulation and the normal endogenous regulation of the uterine bleeding cycle.
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On evaluating the contraceptive potential of the progestogen chlormadinone acetate in a daily dosage range of 0.5 mg. to 4 mg., a sensitivity differential was found between dosage and the development and degree of (1) inhibition of cervical mucus fluidity, (2) suppression of the endometrium, and (3) inhibition of ovulation (Rudel, 1964 ; Rudel et al., 1965 Rudel et al., , 1967 MartinezManautou and Rudel, 1967) . Within this range the highest doses produced all three effects, whereas on reducing the dosage to 0.5 mg. only inhibition of the cervical mucus was uniformly maintained; there was some endometrial suppression and, to a lesser degree, inhibition of ovulation. Though, originally, small numbers of women were studied, no pregnancies were seen with chlormadinone acetate 0.5 mg. daily. This suggested a method in which progestogen given uninterruptedly in small daily doses produces contraception without inhibiting Ovarian biopsies were taken in five of these subjects. Twenty of the group had endometrial biopsies, and pregnanediol was estimated in 16 (see Table III ).
4. Cervical Mucus.-Post-coital sperm count and motility in cervical mucus (Sims-Huhner test) were observed between days 9 and 16 in 115 women.
Microscopical examinations were made of the number and motility of spermatozoa in postcoital (one to eight hours, with a mean of five hours) cervical mucus (see Table IV (Table V) .
Adverse Reactions.-Other than bleeding irregularities, the few adverse reactions or complaints, which may or may not be associated with the use of the drug, were generally benign (Table VI) . Either voluntarily, or as a result of method or patient failure, there was a pregnancy incidence. Seven women delivered full-term healthy babies. In addition, of seven abortions reported, only one was known to be spontaneous, and was a normal female foetus. Acceptability.-Acceptance of the method was excellent, and relatively few withdrew from the study. Of 154 (16%) patients discontinuing the programme, only 16 (1.7%) did so because of bleeding irregularities, and 3 (0.3 %) for other medical reasons.
Discussion
Contraceptive action of the progestogen does not depend on the interruption of gonadotrophic and gonadal hormone production, as indicated by the high incidence of normal secretory and irregular secretory endometria (65.3 %, Table II ). The 24-hour urinary pregnanediol excretions tend to confirm this (Table III) . Culdoscopic visualization of the ovary and ovarian biopsies demonstrating corpora lutea also indicate normal gonadal function (Table III) .
If family planning is to succeed in the developing countries it is vitally important to control fertility as soon after delivery as possible. Since breast-feeding is the main source of safe and adequate nutrition in these countries, it is essential that the contraceptive method does not reduce lactation. Once nursing needs are established, hormones, even oestrogen, do not appear to reduce lactation, but since lactation is susceptible to hormonal inhibition In the immediate post-partum period, objective observations are necessary before we can state to what extent, if any, chlormadinone acetate inhibits lactation.
Summary
Chlormadinone acetate, one tablet (0.5 mg.) daily, was given without interruption to two groups of fertile women, 945 nonlactating and 100 lactating, for contraception, for a total of 8,652 months. Conception was successfully prevented without inhibiting ovulation, and with endogenoas hormonal control of cycle bleeding.
Whereas endometrial suppression and inhibition of cervical mucus demonstrated the anti-oestrogenic property of the progestogen, the degree of fertility protection cannot be explained solely on these mechanisms.
Chlormadinone acetate provides contraception during the lactation period and was not found to interfere with nursing needs.
Other than bleeding irregularities, which may be overcome by using still lower dosage, chlormadinone acetate was found to be remarkably benign.
